OncLive TV

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.

David O’Malley, MD, discusses the state of immunotherapy in ovarian cancer.

Larry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Tatyana Feldman, MD, discusses the shortcomings of PET scan in Hodgkin lymphoma.

David P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.

Ivy P. Altomare, MD, discusses the management of patients with immune thrombocytopenia purpura.

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.